Lypohypertrophy in patients receiving insulin therapy: state of the art

As known insulin therapy is associated with induration of subcutaneous fat at injections sites called lypohypertrophy. It develops at any age and at anysite regardless of duration of the treatment. The size of lypohypertrophy varies in a wide range. Numerous studies have been conducted to elucidatem...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natalya Ivanovna Volkova, Il'ya Yur'evich Davidenko
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2011
Materias:	lypohypertrophy insulin therapy diabetes mellitus ultrasonography insulin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/9549e1ced11c4328a2c381ff837b92b1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9549e1ced11c4328a2c381ff837b92b1
record_format	dspace
spelling	oai:doaj.org-article:9549e1ced11c4328a2c381ff837b92b12021-11-14T09:00:16ZLypohypertrophy in patients receiving insulin therapy: state of the art2072-03512072-037810.14341/2072-0351-5642https://doaj.org/article/9549e1ced11c4328a2c381ff837b92b12011-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5642https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378As known insulin therapy is associated with induration of subcutaneous fat at injections sites called lypohypertrophy. It develops at any age and at anysite regardless of duration of the treatment. The size of lypohypertrophy varies in a wide range. Numerous studies have been conducted to elucidatemechanisms of lypohypertrophy (LH) and its risk factors including young age, low or high body mass index, frequency of the change of needles andinjection sites, female gender, and type 1 diabetes mellitus. It was shown that insulin crystals induce a local immune reaction and thereby interfere withadipocyte differentiation. At the same time, patients with LH have elevated titters of anti-insulin antibodies. The problem with LH is uncontrollableabsorption of insulin from injection sites. We noticed that patients with a target glucose level due to insulin therapy undergo its apparently causelessperiodic rises. Comparative ultrasonic examination of subcutaneous fat at different injection sites and control body areas revealed specific pathologicalchanges in adipose issue. This finding provided a basis for the hypothesis that LH can be detected by ultrasonography of subcutaneous fat. It wasconfirmed by the results of examination of 50 patients with DM1 treated with insulin of whom 41 were found to have pathological changes at injectionsites.Natalya Ivanovna VolkovaIl'ya Yur'evich DavidenkoEndocrinology Research Centrearticlelypohypertrophyinsulin therapydiabetes mellitusultrasonographyinsulinNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 14, Iss 2, Pp 86-89 (2011)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	lypohypertrophy insulin therapy diabetes mellitus ultrasonography insulin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	lypohypertrophy insulin therapy diabetes mellitus ultrasonography insulin Nutritional diseases. Deficiency diseases RC620-627 Natalya Ivanovna Volkova Il'ya Yur'evich Davidenko Lypohypertrophy in patients receiving insulin therapy: state of the art
description	As known insulin therapy is associated with induration of subcutaneous fat at injections sites called lypohypertrophy. It develops at any age and at anysite regardless of duration of the treatment. The size of lypohypertrophy varies in a wide range. Numerous studies have been conducted to elucidatemechanisms of lypohypertrophy (LH) and its risk factors including young age, low or high body mass index, frequency of the change of needles andinjection sites, female gender, and type 1 diabetes mellitus. It was shown that insulin crystals induce a local immune reaction and thereby interfere withadipocyte differentiation. At the same time, patients with LH have elevated titters of anti-insulin antibodies. The problem with LH is uncontrollableabsorption of insulin from injection sites. We noticed that patients with a target glucose level due to insulin therapy undergo its apparently causelessperiodic rises. Comparative ultrasonic examination of subcutaneous fat at different injection sites and control body areas revealed specific pathologicalchanges in adipose issue. This finding provided a basis for the hypothesis that LH can be detected by ultrasonography of subcutaneous fat. It wasconfirmed by the results of examination of 50 patients with DM1 treated with insulin of whom 41 were found to have pathological changes at injectionsites.
format	article
author	Natalya Ivanovna Volkova Il'ya Yur'evich Davidenko
author_facet	Natalya Ivanovna Volkova Il'ya Yur'evich Davidenko
author_sort	Natalya Ivanovna Volkova
title	Lypohypertrophy in patients receiving insulin therapy: state of the art
title_short	Lypohypertrophy in patients receiving insulin therapy: state of the art
title_full	Lypohypertrophy in patients receiving insulin therapy: state of the art
title_fullStr	Lypohypertrophy in patients receiving insulin therapy: state of the art
title_full_unstemmed	Lypohypertrophy in patients receiving insulin therapy: state of the art
title_sort	lypohypertrophy in patients receiving insulin therapy: state of the art
publisher	Endocrinology Research Centre
publishDate	2011
url	https://doaj.org/article/9549e1ced11c4328a2c381ff837b92b1
work_keys_str_mv	AT natalyaivanovnavolkova lypohypertrophyinpatientsreceivinginsulintherapystateoftheart AT ilyayurevichdavidenko lypohypertrophyinpatientsreceivinginsulintherapystateoftheart
_version_	1718429595360821248

Lypohypertrophy in patients receiving insulin therapy: state of the art

Ejemplares similares